SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as investors are weighing the impact of Gravity SUV deliveries and new partnerships against concerns about potential dilution and the company's ability to meet production targets. Community discussions revolve around the company's long-term viability, particularly its cash burn rate and the effectiveness of recent marketing efforts. Sentiment is mixed, with some bulls touting the quality of Lucid's vehicles, while bears point to the company's financial challenges and competitive pressures within the EV sector.

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype Crypto is trending due to increased volume and renewed attention, particularly around its DEX and L1 ecosystem. The community is actively discussing potential breakout ranges and points to its potential as the 'house of all finance,' with some suggesting it could rival major platforms. Recent news of an AI bot launch and quantum-resistant infrastructure may also be driving interest.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending as discussions around a potential acquisition of Warner Bros. Discovery ($WBD) heat up, with reports suggesting a $60 billion bid involving private equity firms. Community members are debating the merits of the deal, potential regulatory hurdles, and whether CEO David Ellison can successfully navigate the complexities of a major media merger, while some express concern about overpaying for WBD and its debt.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma ($XPL) is trending amid discussions about its listing on a Chinese exchange and the broader implications of stablecoin developments, including a Federal Reserve conference on the topic. Community members are weighing the potential impact of these events, with some pointing to its underlying technology and others expressing caution due to recent price volatility. There is also discussion around potential connections to other projects and exchanges.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR is trending due to positive clinical trial data for its hepatitis delta treatment and the announcement of an upcoming Phase 3 registrational program, sparking optimism about its potential to address a rare and life-threatening condition. Community discussions revolve around the company's promising pipeline, strong cash position, and potential partnerships, particularly with GlaxoSmithKline, as well as recent insider activity and analyst ratings. Some investors also express concerns about dilution and the timing of data releases.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen (BIIB) is trending due to a flurry of activity surrounding its pipeline and potential strategic moves, including a confirmed unsolicited acquisition proposal for Sage Therapeutics (SAGE). While some analysts express concerns about revenue and future growth, the community is discussing the potential for undervaluation and a turnaround, particularly with advancements in Alzheimer's treatments and new drug launches offsetting multiple sclerosis portfolio challenges. Chatter also highlights a C5aR license agreement and its potential read-through to InflaRx.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending as investors discuss the recent pullback and potential for a rebound. Community members are pointing to upcoming earnings and broader sector trends, along with potential deregulation, as possible catalysts while closely monitoring insider activity and institutional investment.

Ball Corp. engages in the supplies of aluminum packaging for the beverage, personal care, and household products industries. It operates through the following segments: Beverage Packaging North and Central America, Beverage Packaging South America, and Beverage Packaging Europe, Middle East and Africa (EMEA). The Beverage Packaging North and Central America segment includes multi-year supply contracts to fillers of carbonated soft drinks, beer, energy drinks, and other beverages. The Beverage Packaging South America segment includes beverage containers in South America, and the manufacture of substantially all the metal beverage containers in Brazil. The Beverage Packaging EMEA segment consists of metal beverage containers in Europe, and other packaging materials used by the European beer and carbonated soft drink industries. The company was founded by Edmund Burke Ball, Frank Clayton Ball, George A. Ball, Lucius Lorenzo Ball, and William Charles Ball in 1880 and is headquartered in Westminster, CO.

Ball Corp.

Recent analyst rating adjustments and price target reductions have spurred discussion around $BALL. The community is also closely monitoring the completed sale of Ball's Russian beverage packaging business and its impact on the company's financials. Additionally, new partnerships are being weighed against concerns about aluminum costs and demand changes.

Unum Group engages in the provision of financial protection benefits. Its services include disability, life, accident, critical illness, dental, vision, and other related services. It operates through the following segments: Unum US, Unum International, Colonial Life, Closed Block, and Corporate. The Unum US segment focuses on group disability, group life and accidental death and dismemberment products, and supplemental and voluntary lines of business. The Unum International segment engages in the operations of the UK business, which includes insurance for group long-term disability, group life, and supplemental lines of business that include dental, individual disability, and critical illness products. The Colonial Life segment includes insurance for accident, sickness, disability products, life products, and cancer and critical illness products. The Closed Block segment consists of individual disability, group and individual long-term care, and other insurance products no longer actively marketed. The Corporate segment refers to investment income on corporate assets and other corporate income and expenses not allocated to a line of business. The company was founded in 1848 and is headquartered in Chattanooga, TN.

Unum Group

Unum Group ($UNM) is trending due to recent analyst rating updates and target price increases, reflecting optimism about the company's financial outlook. The community is actively discussing potential breakout patterns and the stock's performance relative to the broader market. Positive analyst sentiment is driving interest in UNM, which operates within the insurance sector.

Clanker is an autonomous agent for deploying tokens. Currently, users may request clanker to deploy an ERC-20 token on Base by tagging it @clanker on Farcaster.

tokenbot

Clanker Crypto ($CLANKER) is trending due to its recent activity and small circulating supply, leading to volatile spikes. The community is closely watching for potential Coinbase integration and how that might affect the token's price. Some users also mention its potential within the AI space and the broader Base App ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Leerink lowered its price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 on Friday, following the company's announcement that it has voluntarily withdrawn its application for the approval of Fanskya to the U.S. Food and Drug Administration for the treatment of Fanconi Anemia.The analyst kept a ‘Market Perform’ rating on the shares, according to TheFly. The new price target, however, implies a potential upside of approximately 118% from the stock’s closing price on Thursday.Rocket Pharma <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036125037163/ef20056613_8k.htm">stated</a> in a filing with the Securities and Exchange Commission that the decision to withdraw the application for the gene therapy follows its decision to focus its resources on programs with the clearest regulatory and commercial pathways. The decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya or RP-L102, the company said.“Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable,” it added.The company ceased internal investment in Fanskya in July 2025 and withdrew its application with the European Medicines Agency (EMA) as part of a pipeline prioritization and corporate reorganization plan. The company had then warned that FDA approval of Fanskya is no longer expected in 2026.The therapy was tested in the treatment of Fanconi Anemia, a rare, inherited disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to symptoms like fatigue, bleeding, and infections, as well as physical abnormalities and a significantly increased risk of certain cancers. &nbsp;The company said on Friday that it will consider external partnership opportunities to advance Fanskya in the future. “Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program,” it said.<a href="https://stocktwits.com/symbol/RCKT">Shares of RCKT</a> fell 2% at the time of writing. On Stocktwits, retail sentiment around RCKT remained within the ‘bearish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_57_15_PM_png_0ff4527f20.webp" alt="RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure> In August, Rocket Pharma <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> that the FDA had lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.RCKT stock is down by 75% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/chCuoM8R3QK">Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sculpture depicting a DNA strand in front of the Lawrence Hall of Science at UC Berkeley on Saturday, March 31, 2018. (Photo By Paul Chinn/The San Francisco Chronicle via Getty Images)

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 

Equity

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 


RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of immunomodulation required for Sarepta Therapeutics' gene therapy (SRPT) Elevidys.The FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy (DMD) patients on Elevidys, Citi said, as per TheFly. Siromilus belongs to a group of medicines known as immunosuppressive agents and has shown promise in managing certain aspects of liver disease and its complications.Citi has a ‘Sell’ rating and a $14 price target on <a href="https://stocktwits.com/symbol/SRPT">Sarepta</a> shares. On Stocktwits, retail sentiment around Sarepta fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:563/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_2_11_08_PM_png_5b28899976.webp" alt="SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="64"><figcaption>SRPT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>Citi made the observations in light of the FDA’s recommendations for Rocket Pharmaceuticals (RCKT) made public earlier in the day.Rocket <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> earlier on Wednesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said.The agency allowed the trial to resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing and with an immunomodulatory regimen more closely reflecting the one administered in an early-stage study pediatric cohort.Sarepta, like Rocket Pharma, has been plagued by patient deaths. It's gene therapy, Elevidys, a medicine intended for the treatment of Duchenne muscular dystrophy (DMD), created safety concerns following the death of two patients after treatment earlier this year. Both non-ambulatory patients suffered from acute liver failure.Sarepta has now resumed shipments for ambulatory individuals after a temporary pause initiated in late July. The company is now working with the FDA on the safety labelling process and risk-mitigation approach for non-ambulatory individuals.SRPT stock is down by 83% this year and by about 86% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/regeneron-says-fda-will-take-more-time-to-review-its-two-eylea-hd-submissions/chsitx3Rdht">Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 

Rocket Pharmaceuticals, Inc. (RCKT) on Wednesday said that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease.The hold, <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-downgraded-after-patient-death-but-retail-bullish/ch0oee8RbrA">imposed</a> roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold">said</a>. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.Rocket Pharma stock shot up 25% in Wednesday’s pre-market session following the development. On Stocktwits, retail sentiment around RCKT rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from 'low' to 'normal' levels.&nbsp;Danon disease is a rare, genetic disorder primarily affecting the heart, skeletal muscles, and sometimes the brain. It's characterized by weakening of the heart muscle, muscle weakness, and intellectual disability.Following the death of a patient, Rocket paused further dosing in the mid-stage study, and on May 23, the FDA placed a clinical hold on the trial to allow for further evaluation. The trial can now resume at an adjusted dose of RP-A501 in three patients, with a minimum four-week interval between dosing, followed by additional patients to complete the trial. The low dose has been determined as most likely to confer the safety and efficacy identified in the low-dose early-stage study cohorts, the company said.Rocket also said that it will collaborate with investigators to implement an immunomodulatory regimen more closely reflecting the one administered in the early-stage study pediatric cohort. Further updates about the mid-stage study can be expected following review of data from the next three patients, the company said.RCKT stock is down by 77% this year and by about 85% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rocket Pharma Stock Up 25% Pre-Market Today? 

The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

RCKT Stock Tanks on Patient Death in Danon Disease Study

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Rocket Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

RCKT
Rocket Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RCKT News

RCKTRocket Pharmaceuticals Inc